Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G2QG
|
|||
| Former ID |
DIB019307
|
|||
| Drug Name |
PMID16290936C1b
|
|||
| Synonyms |
736144-17-5; GTPL8613; CTK2H1087; DTXSID70658350; BDBM50148296
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C16H23NO3
|
|||
| Canonical SMILES |
CCCCC(C=O)NC(=O)OC(C)CC1=CC=CC=C1
|
|||
| InChI |
1S/C16H23NO3/c1-3-4-10-15(12-18)17-16(19)20-13(2)11-14-8-6-5-7-9-14/h5-9,12-13,15H,3-4,10-11H2,1-2H3,(H,17,19)/t13-,15-/m0/s1
|
|||
| InChIKey |
WNKGMQLRHKONID-ZFWWWQNUSA-N
|
|||
| CAS Number |
CAS 736144-17-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin H (CTSH) | Target Info | Inhibitor | [1] |
| Cathepsin K (CTSK) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | |||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Trafficking and processing of endosomal TLR | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.